ReviewAllergy, asthma & immunology research2020
Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma.
Review in Allergy, asthma & immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Dupilumab in Children With Moderate-to-Severe Asthma: A Systematic Review of Emerging Phase 3 Evidence.Pediatric pulmonology · 2025Pooled it
- Association between asthma control and health-related quality of life in severe asthma: a cross-sectional study from KoSAR.ERJ open research · 2025Article
- Oral mucosal lesions in children with severe asthma and acute respiratory viral infections.Clinical oral investigations · 2025Article
- Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2025Article
- Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR.Allergy, asthma & immunology research · 2024Article
- Work-related asthma in adults with severe asthma from the Korean Severe Asthma Registry (KoSAR).The World Allergy Organization journal · 2024Article
- Biologics in Severe Asthma: An Ideal Choice for Achieving Control.Allergy, asthma & immunology research · 2024Article
- Tissue Inhibitor of Metalloproteinase-1 Enhances Eosinophilic Airway Inflammation in Severe Asthma.Allergy, asthma & immunology research · 2023Article
- Development and linguistic validation of the Korean version of the Severe Asthma Questionnaire.Journal of thoracic disease · 2023Article
- Relationships Between High-Resolution Computed Tomographic Features and Lung Function Trajectory in Patients With Asthma.Allergy, asthma & immunology research · 2023Article
- Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea.The World Allergy Organization journal · 2022Article
- Effects of Asthma Medication Type on Asthma Exacerbation in a Real-World Setting.Yonsei medical journal · 2022Article
- Clinical Characteristics and Disease Burden of Severe Asthma According to Oral Corticosteroid Dependence: Real-World Assessment From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2022Article
- Severe asthma in children: An official statement from Saudi Pediatric Pulmonology Association.Saudi medical journal · 2022Article
- Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis.Allergy, asthma & immunology research · 2022Article
- Dupilumab Treatment for Asthma: On the Road to a New Horizon Beyond Ethnic Differences?Allergy, asthma & immunology research · 2022Article
- The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma.The Korean journal of internal medicine · 2022Review
- Sanzi Yangqin Decoction Alleviates Allergic Asthma by Modulating Th1/Th2 Balance: Coupling Network Pharmacology with Biochemical Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Additive Effect of Obesity and Dyslipidemia on Wheezing in Korean Adults: A Nationwide Representative Survey Study.Allergy, asthma & immunology research · 2021Article
- S100A9 in adult asthmatic patients: a biomarker for neutrophilic asthma.Experimental & molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
Severe asthma (SA) presents in about 3%-5% of adult asthmatics and is responsible for over 60% of asthma-related medical expenses, posing a heavy socioeconomic burden. However, to date, a precise definition of or clear diagnostic criteria for SA have not been established, and therefore, it has been challenging for clinicians to diagnose and treat this disease. Currently, novel biologics targeting several molecules, such as immunoglobulin E, interleukin (IL)5, and IL4/IL13, have emerged, and many new drugs are under development. These have brought a paradigm shift in understanding the mechanism of SA and have also provided new treatment options. However, we need to agree on a precise definition of and its diagnostic criteria for SA. Additionally, it is necessary to explain the diagnostic criteria and to summarize current standard and additional treatment options. This review is an experts' opinion on SA from the Korean Academy of Asthma, Allergy, and Clinical Immunology, the Working Group on Severe Asthma, and aims to provide a definition of and diagnostic criteria for SA, and propose future direction for SA diagnosis and management in Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.